REG - Ondine Biomedical - Leeds Teaching Hospital NHS Trust to use Steriwave

Ondine BiomedicalAnnouncement

06/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240806:nRSF2583Za&default-theme=true

RNS Number : 2583Z  Ondine Biomedical Inc.  06 August 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Leeds Teaching Hospitals NHS Trust to use Steriwave

Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company
pioneering light-activated antimicrobial treatments, and Iskus Health announce
that Leeds Teaching Hospitals NHS Trust will begin using its Steriwave(®)
nasal decolonization technology later this month. Leeds Teaching Hospitals NHS
Trust is one of the largest and busiest acute hospital trusts in the country,
treating 1.5 million patients every year.

Steriwave will be used as part of a quality improvement (QI) initiative to
prevent infections in patients undergoing surgery to remove tumours from the
base of the brain or top of the spine via the nose (endonasal endoscopic
anterior skull base surgery). The key endpoints for the QI initiative will be
reducing post-operative antibiotic use 30 days after surgery, and reducing the
need for outpatient follow-up appointments to treat infections.

Post-surgical infections prolong recovery times, with even minor infections
requiring more follow-up appointments, and treatment often requires prolonged
use of antibiotics. Reducing antibiotic use is also a key aspect of the UK's
5-year action plan for antimicrobial resistance
(https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2024-to-2029)
, which was published in May 2024.

Paul Nix, Rhinology and Anterior Skull Base Surgeon at Leeds Teaching
Hospitals NHS Trust, will lead the Steriwave QI initiative. He says: "There
are great advantages to going through the nose to operate on skull base
tumours because of the minimally invasive access and the fact that patients
have a better quality of life after surgery. However, there is a risk of
infection because we access the surgical site through the nose - a well-known
reservoir for pathogens - and we risk introducing those pathogens into the
brain. Luckily, we have a very low rate of infections, but if a patient gets
an infection like meningitis it can be life-threatening.

"Decolonizing the nose is particularly important for us as, unlike with more
conventional surgeries, we are not able to clean the skin around the incision.
Antibiotics can be used to decolonize the nose but need to be applied by
patients at home for five days before surgery, and patients may not be able to
do this, not to mention the concerns around rising levels of antimicrobial
resistance. The great advantage of Steriwave is that it can be administered
once a patient has been admitted or at short notice for an emergency surgery
and works instantly."

Steriwave is a groundbreaking antimicrobial treatment that uses a
light-activated agent to rapidly eliminate infection-causing pathogens. First,
the agent is applied to each nostril using a nasal swab, then the area is
illuminated with a red light laser. The light activates the photodynamic
agent, causing an oxidative burst that destroys pathogens. This eliminates
infection-causing bacteria, viruses and fungi in a single, 5-minute treatment.
The process works so rapidly that pathogens do not have the opportunity to
develop resistance, making it an effective alternative to antibiotics.

In March 2024, Mid Yorkshire Teaching NHS Trust became the first in the UK to
commercially adopt Steriwave as the standard of care for hip and knee surgery
patients to prevent surgical site infections (SSIs). In June 2024, was added
to the NHS Supply Chain, making it significantly easier for NHS hospitals in
England and Wales to purchase. The NHS Supply Chain is a national body which
manages the sourcing, delivery and supply of healthcare products to the NHS
and healthcare organizations in England and Wales.

 

Enquiries:

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                        +001 (604) 665 0555

 Iskus Health Ltd                           +353 (0) 1 428 7895

 Stuart Murray, Commercial Director

 Singer Capital Markets

(Nominated Adviser and Joint Broker)
 Phil Davies, Sam Butcher                  +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan            +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard          +44 (0)77 1000 5910

 

 

About Leeds Teaching Hospitals NHS Trust

Leeds Teaching Hospitals NHS Trust is one the largest and busiest acute
hospital trusts in the country. We are the local hospital for Leeds and
provide specialist services for our local communities, the Yorkshire and
Humber region and beyond.  

 

Leeds Teaching Hospitals has a budget of more than £1.9 billion and a
21,000-strong staff. Last year, we treated more than 1.6 million patients,
including 97,000 inpatient admissions, 1.2 million outpatient attendances and
344,000 attendances in our Emergency Departments.

Our care and clinical expertise is delivered from seven hospitals on five
sites, and they are all joined by our vision to be the best for specialist and
integrated care.

 

Find out more on our website: Leeds Teaching Hospitals NHS Trust
(leedsth.nhs.uk (https://www.leedsth.nhs.uk/) )

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a clinical Canadian life sciences company and leader
in light-activated antimicrobial therapies (also known as
'photodisinfection'). Ondine has a pipeline of investigational products, based
on its proprietary photodisinfection technology, in various stages of
development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe, the UK-CA
mark, and is approved in Canada and several other countries under the name
Steriwave®. In the US, it has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

About Steriwave(®)

Ondine's Steriwave nasal photodisinfection system is a patented technology
using a proprietary light-activated antimicrobial (photosensitizer) to destroy
bacteria, viruses, and fungi colonizing the nose. The photodisinfection
treatment is carried out by a trained healthcare professional and is an
easy-to-use, painless, two-step process. The photosensitizer is applied to
each nostril using a nasal swab, followed by illumination of the area with a
specific wavelength of red laser light for less than five minutes. The light
activates the photosensitizer, causing an oxidative burst that is lethal to
all types of pathogens without causing long-term adverse effects on the nasal
microbiome. A key benefit of this approach-unlike with antibiotics, which have
resistance rates reported as high as 81%( 1 )(-)is that pathogens do not
develop resistance to the therapy.

 

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections,( 2 ) and the Society for Healthcare
Epidemiology of America (SHEA) guidelines, published in May 2023, recommend
nasal decolonization for major surgical procedures.( 3 )

 

 1  Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical
implications and potential alternatives for the eradication of MRSA. J
Antimicrob Chemother. 2015;70(10):2681-2692. (link
(https://academic.oup.com/jac/article/70/10/2681/829798?login=false) )

 2  Surgical Site Infection Prevention: Key facts on decolonization of nasal
carriers of Staphylococcus aureus. World Health Organization. (link
(https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2)
)

 3  Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent
surgical site infections in acute-care hospitals: 2022 Update. Infect Control
Hosp Epidemiol. 2023;44(5):695-720. (link
(https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/strategies-to-prevent-surgical-site-infections-in-acutecare-hospitals-2022-update/2F824B9ADD6066B29F89C8A2A127A9DC)
)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRKZGGRVKVGDZM